News|Articles|March 13, 2024
Overcoming oncolytic virus therapy production challenges through collaboration
Author(s)ReciBioPharm
Discover how ReciBioPharm’s strategic approach helped to support the rapid delivery of an innovative oncolytic adenovirus therapy for advanced cancer to clinic.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
2
How Biopharma Navigates the 2026 Economic Shift
3
Adenovirus Vectors, Cyclodextrins and the Patient Experience: A Deep Dive
4
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
5